Astellas Pharma Company Top Insiders
| ALPMF Stock | USD 9.52 0.32 3.25% |
Astellas Pharma employs about 14.5 K people. The company is managed by 60 executives with a total tenure of roughly 314 years, averaging almost 5.0 years of service per executive, having 242.03 employees per reported executive. Examination of Astellas Pharma's management performance can provide insight into the company performance.
| Yoshihiko Hatanaka CEO CEO and President and Representative Director |
| Masao Yoshida CEO Senior Executive Officer and Presidentident and CEO of Subsidiaries |
Astellas |
Astellas Pharma Management Team Effectiveness
The company has return on total asset (ROA) of 0.0653 % which means that it generated a profit of $0.0653 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0898 %, meaning that it generated $0.0898 on every $100 dollars invested by stockholders. Astellas Pharma's management efficiency ratios could be used to measure how well Astellas Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Astellas Pharma Workforce Comparison
Astellas Pharma is number one stock in number of employees category among related companies. The total workforce of Drug Manufacturers—General industry is presently estimated at about 318,667. Astellas Pharma holds roughly 14,522 in number of employees claiming about 5% of equities under Drug Manufacturers—General industry.
The company has Profit Margin (PM) of 0.09 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.17 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.17. Astellas Pharma Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Astellas Pharma Price Series Summation is a cross summation of Astellas Pharma price series and its benchmark/peer.
Astellas Pharma Notable Stakeholders
An Astellas Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Astellas Pharma often face trade-offs trying to please all of them. Astellas Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Astellas Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Yoshihiko Hatanaka | CEO and President and Representative Director | Profile | |
| Masao Yoshida | Senior Executive Officer and Presidentident and CEO of Subsidiaries | Profile | |
| Yoshiro Miyokawa | Chief Admin. Officer, Chief Compliance Officer, Executive VP, Representative Director, Chairman of Global Compliance Committee and Member of Compensation Committee | Profile | |
| Masafumi Nogimori | Chairman of the Board, Representative Director | Profile | |
| Yukihiko Sato | President of Sales and Marleting, Sr. Corporate Executive and Sr. VP | Profile | |
| Nate Crisel | Vice President - Real World Informatics & Analytics | Profile | |
| Masatoshi Kuroda | Executive Officer and Presidentident of Subsidiary | Profile | |
| Kazuhiro Sako | Executive Officer and Presidentident of Subsidiary | Profile | |
| Bernhardt Zeiher | President - Development, Chief Medical Officer | Profile | |
| Yoshitsugu Shitaka | Executive Officer and Presidentident of Subsidiary | Profile | |
| Yasumasa Masuda | CFO, Sr. VP and Sr. Corporate Executive | Profile | |
| Mitsunori Matsuda | Sr. VP of Technology and Sr. Corporate Executive | Profile | |
| Yutaka Kase | Independent Director | Profile | |
| Hironobu Yasuda | Independent Director | Profile | |
| Naoki Okamura | Executive Officer, Director of Business Planning | Profile | |
| Eisuke Nozawa | Executive Officer, Director of Pharmaceutical Affairs | Profile | |
| Hideki Shima | Executive Officer, Director of Technology Planning in Main Pharmaceutical Technology Unit | Profile | |
| Akihiko Iwai | Executive Officer, Director of Research Portfolio & Science in Main Research Unit | Profile | |
| Taiji Sawamoto | Executive Officer, Director of Clinical Pharmacology in Main Development Unit | Profile | |
| Yuichi Murakami | Director of Accounting | Profile | |
| Akira Kamimura | Director of Accounting | Profile | |
| Fumiaki Sakurai | Executive Officer, Director of Human Resources | Profile | |
| Mamoru Sekiyama | Independent Director | Profile | |
| Masaaki Hirano | Executive Officer, Director of Business Planning | Profile | |
| Noriyuki Uematsu | Independent Director | Profile | |
| Takahisa Iizuka | Executive Officer, Director of Sales Promotion | Profile | |
| Tomokazu Fujisawa | Director | Profile | |
| Hiroo Sasaki | Independent Director | Profile | |
| Takuya Oshida | Executive Officer, Chief Director of Medical Affairs | Profile | |
| Shigeki Tanaka | Executive Officer, Director of 1st Japan & Asia Clinical Development in Main Development Unit | Profile | |
| Atsushi Kamide | Executive Officer, Director of Product Management in Main Sales Unit | Profile | |
| Etsuko Okajima | Independent Director | Profile | |
| Keiko Yamagami | Independent Director | Profile | |
| Chikashi Takeda | Executive Officer, Director of Business Planning | Profile | |
| Shoji Yokota | Executive Officer, Director of Technology Promotion in Main Technology Unit | Profile | |
| Wataru Uchida | Executive Officer, Director of Pharmacology Research Institute in Main Research Unit | Profile | |
| Chihiro Yokota | Executive Officer, Director of Licensing and Alliance | Profile | |
| Hitoshi Kanamori | Independent Director | Profile | |
| Tadashi Hara | Executive Officer, Director of Sales Strategy in Main Sales Unit | Profile | |
| Toru Yoshimitsu | Executive Officer, Director of Product Strategy | Profile | |
| Kazunori Okimura | Executive Officer, Director of Legal Affairs & Compliance | Profile | |
| Makoto Takeuchi | Executive Officer, Director of Research Promotion | Profile | |
| Hiroko Sakai | Director | Profile | |
| Yoshiharu Aizawa | Independent Director | Profile | |
| Naoki BSc | Chief VP | Profile | |
| Shiro Yamamoto | Executive Officer, Manager of Tokyo Office in Main Sales Unit | Profile | |
| Linda Friedman | General Counsel | Profile | |
| Yukio Matsui | Executive Officer, Manager of Global Marketing Strategic Function | Profile | |
| Nobue Yasuda | Gen Department | Profile | |
| Collette Taylor | VP HR | Profile | |
| Minoru Kikuoka | CFO Officer | Profile | |
| Katsuyoshi Sugita | Chief Officer | Profile | |
| Catherine Levitt | G Counsel | Profile | |
| Kiyotaka Hayashi | Executive Officer, Manager of Kyushu Office in Main Sales Unit | Profile | |
| Nobuaki Tanaka | Executive Officer, Manager of Chiba Office in Main Sales Unit | Profile | |
| Katzumi Ozawa | Executive Officer, Manager of Tokyo Office in Main Sales Unit | Profile | |
| Stig Ogata | VP Communications | Profile | |
| Sef Kurstjens | Chief Medical Officer | Profile | |
| Kenji Yasukawa | Senior Executive Officer, Manager of Vaccine Business Promotion Office | Profile | |
| Yasuhiro Kanzaki | Executive Officer, Manager of Osaka Office in Main Sales Unit | Profile |
About Astellas Pharma Management Performance
The success or failure of an entity such as Astellas Pharma often depends on how effective the management is. Astellas Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Astellas management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Astellas management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. ASTELLAS PHARMA operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 14522 people.
The data published in Astellas Pharma's official financial statements usually reflect Astellas Pharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Astellas Pharma. For example, before you start analyzing numbers published by Astellas accountants, it's critical to develop an understanding of what Astellas Pharma's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Astellas Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Astellas Pharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Astellas Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Astellas Pharma. Please utilize our Beneish M Score to check the likelihood of Astellas Pharma's management manipulating its earnings.
Astellas Pharma Workforce Analysis
Traditionally, organizations such as Astellas Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Astellas Pharma within its industry.Astellas Pharma Manpower Efficiency
Return on Astellas Pharma Manpower
| Revenue Per Employee | 89.3M | |
| Revenue Per Executive | 21.6B | |
| Net Income Per Employee | 8.5M | |
| Net Income Per Executive | 2.1B | |
| Working Capital Per Employee | 33.8M | |
| Working Capital Per Executive | 8.2B |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Astellas Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Astellas Pink Sheet analysis
When running Astellas Pharma's price analysis, check to measure Astellas Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astellas Pharma is operating at the current time. Most of Astellas Pharma's value examination focuses on studying past and present price action to predict the probability of Astellas Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astellas Pharma's price. Additionally, you may evaluate how the addition of Astellas Pharma to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |